CANINE DEGENERATIVE MYELOPATHY: FROM GENE MUTATION DISCOVERY TO CLINICAL TRIALS
Degenerative myelopathy (DM) is an inherited, adult-onset disease of the spinal cord causing progressive weakness and paralysis of the hind limbs and eventually all limbs. DM has clinical, histopathologic, and genetic parallels to amyotrophic lateral sclerosis (ALS - Lou Gehrig's disease) in humans.
Mutations in an enzyme that converts superoxide to water and hydrogen peroxide, superoxide dismutase 1 (SOD1), have been linked to DM and human ALS. These discoveries have guided studies to further understand natural history, establish biomarkers, and initiate clinical trials for therapeutic strategies.
Join us in this webinar for a better understanding of DM including:
- Genetic testing results as a risk factor for canine degenerative myelopathy
- The neurologic progression in affected patients in terms of disease spread and changes in neuroanatomic localization
- The pathophysiology of the mutated SOD1 protein and its consequences in the multifactorial pathogenesis of canine degenerative myelopathy
- A platform of clinical trial designs and their potential applications in veterinary medicine
Click here to read a brief summary of this webinar.
Original Air Date: October 17, 2019
Learn more about Dr. Coates' CHF-funded research:
Grant 02165-MOU: Identification of Biomarkers and Therapeutic Targets for Canine Degenerative Myelopathy: The Search for A Cure
Grant 02658: Characterization of Sensory Neuronal and Muscle Pathology in Canine Degenerative Myelopathy to Identify Targets for Therapeutic Intervention
Related Articles
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.
